Sequent Scientific Limited — PPTs, 13-11-2024: Investor Presentation

SeQuent Scientific Limited continues to demonstrate robust growth in its performance for Q2 FY25, with revenues increasing 6.6% YoY to ₹3,686 million, driven by strong demand across key markets and a focus on formulation expansion. The company's first half saw an impressive overall revenue growth of 11.7% YoY. Gross margins are trending upwards, attributed to cost improvement initiatives and an enhanced portfolio mix. EBITDA for Q2 rose dramatically, reaching ₹447 million, reflecting a 70% YoY increase, while the first half EBITDA soared 161% YoY to ₹930 million.

A major strategic development is the proposed merger with Viyash Life Sciences, aimed at creating a comprehensive global pharmaceuticals platform. The merger is progressing well, expected to finalize within 12-15 months, pending regulatory approvals. Viyash also reported strong results with a 5.4% YoY revenue increase and a 30.6% rise in EBITDA for the first half of FY25. The combined entity is set to leverage enhanced capabilities and broaden market reach, creating a positive outlook for growth and shareholder value as the integration unfolds.